CoChat
Sign Up
Cited by 11Treatment of Major DepressionBipolar Disorder and TreatmentAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Number of illness episodes as predictor of residual symptoms in major depressive disorder

Serafini, Gianluca, Nebbia, Jacopo, Cipriani, Nicolò, Conigliaro, Claudia, Erbuto, Denise, Pompili, Maurizio, Amore, Mario·2018·Psychiatry Research
DOI 10.1016/j.psychres.2017.09.026
Open this paper in CoChat — free account

Abstract

Notwithstanding major depressive disorder (MDD) is a recurring and chronic condition, relatively few variables have consistently been shown to predict its course. Residual depressive symptoms may be associated with disability and functional impairment but few studies evaluated clinical correlates associated with these symptoms and their impact on functioning after adjustment for potential confounders. Therefore, our study aimed to investigate factors associated with residual depressive symptoms and their impact on the course of MDD. The sample consisted of 210 consecutive MDD euthymic outpatients (67.6% females; mean age = 52.1 ± 15.5), admitted to the Section of Psychiatry, University of Genoa (Italy). Residuals depressive symptoms were significantly associated with female gender; use of short half-life benzodiazepines; longer duration of the current depressive episode; higher number of illness episodes; and higher duration of illness. Conversely, prior treatment with first-generation antipsychotics, later age of illness onset and first hospitalization were less frequently observed among patients with residual symptoms. After multivariate analyses, only duration of current illness episodes (ß = 0.003; p = <0.005) and substance abuse (ß = 0.042; p = <0.05) remained significantly associated with residual symptoms. Our findings indicate that residual depressive symptoms conferred a pernicious illness course in this specific cohort of MDD patients. Future trials mainly targeting these burdensome symptoms are warranted.

Integrity signals

Registry

Crossref · 10.1016/j.psychres.2017.09.026

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Remission rates are lower in treatment-resistant depression, which is associated with a higher risk of recurrence, substance abuse, and suicidal behavior.

    “These remission rates are lower in treatment-resistant depression (TRD) [5] which is associated with a higher risk of recurrence, substance abuse, and suicidal behavior [6,7].”

    From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [6]

  • Patients with residual depression symptoms despite responding to treatment have a higher risk of recurrence.

    “In addition, patients who had residual depression symptoms despite responding to treatment, had higher risk of recurrence (Serafini et al., 2018; Nierenberg et al., 2010; Judd et al., 1998) [19, 24, 25].”

    From Predictors of recurrence of major depressive disorder (2020) · cites this paper as Serafini et al., 2018

Cites

Flagged first, then by citations

1 of the 44 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Serafini, G., Nebbia, J., Cipriani, N., Conigliaro, C., Erbuto, D., Pompili, M., & Amore, M.
Affiliations
  • University of Genoa (IT)
  • Azienda Ospedaliera Sant'Andrea (IT)
Corresponding author
Serafini, Gianluca
ORCID
Venue
Psychiatry Research
Publisher
Elsevier BV
Published
2018-04
Volume
262
Pages
469-476
ISSN
0165-1781 (ISSN-L)
DOI
10.1016/j.psychres.2017.09.026
OpenAlex
W2754635463
Cited by
11
References
44
Citations by year
2025: 1 · 2024: 1 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 2
FWCI
1.15
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Psychiatry Research (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Funders
World Health Organization
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
major depressive disorder, residual depressive symptoms, clinical course, disease duration, substance abuse, benzodiazepines, typical antipsychotics, functional disability, predictors of treatment outcome
MeSH terms
Adult, Aged, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Italy, Male, Middle Aged, Time Factors, Cohort Studies, Outcome Assessment, Health Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review